Array BioPharma announced updated results from the 30 patient safety lead-in of the Phase III BEACON CRC trial evaluating the triplet combination of encorafenib, in patients with BRAF-mutant metastatic colorectal cancer (CRC) whose disease has progressed after one or two prior regimens. The randomized, open-label, global trial enrolled 30 patients who were treated in the safety lead-in and received the triplet combination (encorafenib 300mg daily, binimetinib 45mg twice daily and cetuximab per label). The confirmed overall response rate (ORR) in patients with the BRAFV600E mutation was 48%, and three patients achieved complete responses (CR). Further, the ORR was 62% in the 16 patients (10/16) who received only one prior line of therapy. These data represent substantial improvements compared to several separate historical published standard of care benchmarks for this population. In the safety lead-in, the triplet combination was generally well-tolerated. The most common grade three or four AEs seen in at least 10% of patients were fatigue (4/30), urinary tract infection (3/30), increased aspartate aminotransferase (AST; 3/30) and increased blood creatine kinase (CK; 3/30). All patients with elevated baseline levels of the tumor markers CEA and CA19-9 had a reduction from baseline, with similar and substantial (median 83% – 96%) reductions across both markers in patients with objective responses and those with stable disease. The enrollment in the randomized portion of the BEACON CRC trial is ongoing.